1. Woodcock J, Behrman RE, Dal Pan GJ. Role of postmarketing surveillance in contemporary medicine. Annu Rev Med. 2011;62:1–10. https://doi.org/10.1146/annurev-med-060309-164311.
2. Code of Federal Regulations Title 21, Section 314.70. Supplements and other changes to an approved NDA. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.70. Accessed 16 Nov 2021
3. Code of Federal Regulations Title 21, Section 201.56(a)(1). Requirements on content and format of labeling for human prescription drug and biological products. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=201.56. Accessed 16 Nov 2021
4. Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling. FDA Guidance Document. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/warnings-and-precautions-contraindications-and-boxed-warning-sections-labeling-human-prescription. Accessed 26 Oct 2021.
5. Adverse Reactions Section of Labeling. FDA Guidance Document. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse-reactions-section-labeling-human-prescription-drug-and-biological-products-content-and. Accessed 26 Oct 2021.